COMMUNIQUÉS West-GlobeNewswire

Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026
28/10/2026
CAMBRIDGE, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living [...]
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
28/10/2026
CAMBRIDGE, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core [...]
STERIS Announces Dividend of $0.69 per share
28/10/2026
DUBLIN, IRELAND, Oct. 28, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly dividend of $0.69 per share. The dividend is payable on [...]
LENZ Therapeutics Reports Third Quarter 2026 Financial Results, Announces Strategic Consumer Marketing Focused Reorganization and CEO Succession
28/10/2026
Q3 2026 VIZZ® product sales increased 50% over prior quarter, with strong momentum continuing into Q4 as consumer awareness broadens and telehealth adoption increases Strategic reorganization to prioritize consumer [...]
DBV Technologies publie ses résultats financiers du troisième trimestre 2026 et fait le point sur ses activités
28/10/2026
DBV Technologies publie ses résultats financiers du troisième trimestre 2026 et fait le point sur ses activités Dépôt auprès de la FDA américaine de la demande de licence de produit biologique (le « BLA ») pour le patch [...]
DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update
28/10/2026
Châtillon, France, October 28, 2026 DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update Submitted the Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in children [...]
Precipio Announces Q3-2026 Shareholder Update Call
28/10/2026
Conference Call will be held on November 10th, 2026, at 5:00 PM EST NEW HAVEN, Conn., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q3-2026 [...]
Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Broader Precision Medicine Strategy
29/10/2026
Live Webcast at 8:30 a.m. ET on Thursday, October 29, 2026 PHILADELPHIA, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, [...]
Major shareholder announcement - BlackRock, Inc.
28/10/2026
ANNOUNCEMENT NO. 323 28 October 2026 Pursuant to section 30 of the Danish Capital Markets Act, notice is hereby given that BlackRock, Inc. has notified ChemoMetec A/S that, on 26 October 2026, BlackRock, Inc. increased [...]
Chiffre d’affaires au Septembre 2026
28/10/2026
Le chiffre d’affaires à fin septembre 2026 s’établit à €4 051m , en progression de +4,7% en base organique par rapport à la même période de 2025 L’ensemble des activités et des régions contribue à la croissance du [...]
Revenue for the nine months ended September 2026
28/10/2026
Revenue at end September 2026 of €4,051m, up +4.7% on an organic basis compared with the same period in 2025 All activities and regions contributed to revenue growth, supported by favourable volume, price and case mix [...]
Nordic Naturals Joins Eudēmonia Summit as Featured Partner and Exhibitor, Hosting Panel on Omega-3s and Healthy Aging
28/10/2026
Watsonville, CA, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Nordic Naturals , the #1 selling omega-3 brand in the U.S.‡, today announced it will be a featured partner and brand presenter at the Eudēmonia Summit, a science-based [...]
Mesa Labs Announces Second Quarter Financial Results Release Date and Earnings Conference Call
28/10/2026
Lakewood, Colo., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”), a global leader in the design and manufacture of critical quality control solutions and [...]
Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results on October 29, 2026
28/10/2026
WATERTOWN, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological [...]
MIMEDX Announces $25 Million Patent License Agreement
28/10/2026
MARIETTA, Ga., Oct. 28, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it has entered into a license agreement with a wound care competitor that resolves [...]
ARS Pharma to Report Third Quarter 2026 Financial Results
28/10/2026
SAN DIEGO, Oct. 28, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from [...]
Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis
28/10/2026
Stockholders approved the conversion of the preferred stock issued in the June 2026 acquisition of Azora Therapeutics Azora’s common stock to begin trading on Nasdaq under the ticker symbol “AZR” New executive [...]
MIMEDX Announces Third Quarter 2026 Operating & Financial Results
28/10/2026
Reports Continued Double-Digit Year-Over-Year Volume Growth for Surgical Franchise Delivers Wound Care Center Volume Growth Both Sequentially and Year-Over-Year Obtained Favorable Federal Court Ruling in AXIOFILL ® [...]
Coherus Oncology Announces Compelling Tagmokitug Interim Clinical Data in Esophageal Cancer and Path to Advance Development
28/10/2026
- 1L ESCC confirmed ORR of 75% irrespective of PD-L1 status, confirmed ORR of 100% for PD-L1- positive, in evaluable patients- -2L ESCC durable clinical benefit observed with a clear dose-response irrespective of PD-L1 [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum